Clinical Trials Logo

Severe Chronic Pain clinical trials

View clinical trials related to Severe Chronic Pain.

Filter by:
  • None
  • Page 1

NCT ID: NCT02268812 Completed - Pain Management Clinical Trials

Patient Registry of Intrathecal Pain Management in Europe for Prialt (Ziconotide Intrathecal Infusion) and Alternative Drugs for the Management of Severe, Chronic Pain.

PRIME
Start date: April 2008
Phase:
Study type: Observational

This is an open-label, long-term, multi-center multi-national post-marketing observational registry. The objective of this study is to monitor the long-term efficacy, safety, tolerability and quality of life outcomes associated with ziconotide (Prialt) and other analgesics utilized in the intrathecal (IT) management of severe chronic pain.

NCT ID: NCT01915147 Completed - Severe Chronic Pain Clinical Trials

A Study to Explore the Influence of Two Opioid Pain Medications on Bacterial Composition in the Gut and Other Gastrointestinal Aspects

Start date: July 2013
Phase: Phase 2
Study type: Interventional

The study is intended to explore changes in the composition and quantity of gut bacteria subject to treatment with strong pain medication. Two pain medications will be compared (OXN PR and OxyPR). Other gastrointestinal parameters will be assessed.

NCT ID: NCT00699335 Completed - Severe Chronic Pain Clinical Trials

Matrifen® for Therapy of Severe Chronic Pain®

Matrix LQ
Start date: June 2008
Phase: N/A
Study type: Observational

The aim of the study was to evaluate the efficacy and safety of Matrifen® in patients with severe and chronic pain who could only be sufficiently treated with opioid analgetics (WHO class 3).

NCT ID: NCT00556270 Completed - Clinical trials for Severe, Chronic Pain

Efficacy of Matrifen in Patients Older Than 18 Years With Severe, Chronic Pain

MATRIX II
Start date: November 2007
Phase: N/A
Study type: Observational

The aim of the study is to evaluate the efficacy and safety of matrifen in patients with severe and chronic pain who can only be sufficiently treated with opioid analgesics (WHO class 3).